Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.86 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.86 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.86 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.86 |
| ▸ | MGLL | Q99685 | 1/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urb-597 SCHEMBL93842 | 0.92 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| Urb-597 SCHEMBL29371698 | 0.92 | FAAH (1.00) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14187855 | 0.91 | FAAH (0.98) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL17175654 | 0.88 | FAAH (0.93) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL4183181 | 0.88 | FAAH (0.71) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL14044821 | 0.87 | FAAH (0.67) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL4965649 | 0.86 | FAAH (0.66) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.86 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL4751725 | 0.85 | FAAH (0.65) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL16118260 | 0.85 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008129129-A1 | HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS | KUOPION YLIOPISTO (FI) | 2008-10-30 | — | — | WO | disclosed |
| EP-1969051-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2008-09-17 | — | — | EP | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030752-A2 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | N.V. ORGANON (NL) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008024139-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007079180-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089845-A1 | METHODS FOR DETERMINING EFFECTIVE DOSES OF FATTY ACID AMIDE HYDROLASE INHIBITORS IN VIVO | FAAH, FAAH2, FADS1 | FAAH 1/4885TRPA1 2368/4885EPHX2 78/4885 |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | FAAH 1/4885TRPA1 1100/4885EPHX2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.